MAP2K7 and neurofibromatosis type 1: Several preclinical studies validated mitogen‐activated protein kinase (MEK), a component of the Ras‐Raf‐MEK‐ERK signaling cascade, as a potential therapeutic target for NF1 tumors and other manifestations.